Trials / Completed
CompletedNCT01428362
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- VIVUS LLC · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VI-1121 | |
| DRUG | Placebo |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2011-09-05
- Last updated
- 2013-12-11
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01428362. Inclusion in this directory is not an endorsement.